Literature DB >> 33157268

FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases.

Kalliopi Zachou1, Vasiliki Lygoura1, Pinelopi Arvaniti1, Georgios Giannoulis1, Nikolaos K Gatselis1, George K Koukoulis2, George N Dalekos3.   

Abstract

INTRODUCTION AND
OBJECTIVES: We assessed FibroMeter virus (FMvirus) and FibroMeter vibration-controlled transient elastography (FMVCTE) in 134 patients with autoimmune liver diseases [ALD, autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC)], in order to assess new potential non-invasive biomarkers of liver fibrosis in patients with ALD, as similar data are missing. PATIENTS AND METHODS: The following groups were included: group 1: n = 78 AIH; group 2: n = 56 PBC. FMvirus and FMVCTE were determined in all 134 patients who underwent liver biopsy and TE the same day with sera collection. In addition, APRI and FIB-4 scores were calculated.
RESULTS: The AUCs for TE and FMVCTE were significantly better (0.809; p < 0.001 and 0.772; p = 0.001, respectively for AIH and 0.997; p < 0.001 and 1; p < 0.001, for PBC) than the other three markers in predicting ≥ F3 fibrosis irrespective of the biochemical activity. FMVCTE and TE had good diagnostic accuracy (75.6% and 73%, respectively) for predicting severe fibrosis in AIH and performed even better in PBC (94.6% and 96.4%, respectively). The cut-offs of TE and FMVCTE had the best sensitivity and specificity in predicting ≥ F3 fibrosis in both AIH and PBC.
CONCLUSIONS: FMVCTE seems to detect severe fibrosis equally to TE in patients with ALD but with better specificity. Biochemical disease activity did not seem to affect their diagnostic accuracy in ALD and therefore, could be helpful for the assessment of fibrosis, especially if they are performed sequentially (first TE with the best sensitivity and then FMVCTE with the best specificity).
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Autoimmune hepatitis; FMVCTE; FMvirus; Liver fibrosis; Primary biliary cholangitis.

Mesh:

Year:  2020        PMID: 33157268     DOI: 10.1016/j.aohep.2020.10.013

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  2 in total

1.  First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.

Authors:  George N Dalekos; Pinelopi Arvaniti; Nikolaos K Gatselis; Anna Samakidou; Stella Gabeta; Eirini Rigopoulou; George K Koukoulis; Kalliopi Zachou
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

2.  Acute non-A, non-B, non-C hepatitis differences and similarities between hepatitis E virus infection and autoimmune hepatitis, with phylogenetic analysis of hepatitis E virus in humans and wild boars.

Authors:  Kalliopi Zachou; Kalliopi Azariadis; Marina Sofia; Aggeliki Lyberopoulou; Pinelopi Arvaniti; Nikolaos Gatselis; Vassiliki Spyrou; Charalambos Billinis; George N Dalekos
Journal:  Ann Gastroenterol       Date:  2022-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.